Metropolis Healthcare Limited (METROPOLIS) Earnings Call Transcript
May 14, 2026
Earnings Call Speaker Segments
Good day, ladies and gentlemen, and welcome to the Q4 and FY 2026 earnings conference call of Metropolis Healthcare Limited, hosted by Ambit Capital. Forward-looking statements about the company may be included in this conference call, and those statements rest on the beliefs, opinions, and expectations of the company as of the date of this call. Future performance of the company is not guaranteed by these statements, and they may involve risks and uncertainties that are difficult to predict. As a reminder, all participant lines will be in the listen-only mode. After the presentation concludes, there will be an opportunity for you to ask questions. If you need any assistance during this conference call, please signal an operator by pressing star and then zero on your touch-tone telephones. Please note that this conference call is being recorded. I now hand the conference over to Mr. Gaurav Tinani from Ambit Capital. Thank you, and over to you, Mr. Tinani.
Thanks, Farrah. Hello, everyone. We at Ambit Capital are glad to have all of you with us for the Q4 and FY 2026 earnings conference call of Metropolis Healthcare Limited. Joining us today are Ms. Ameera Shah, Promoter, Chairperson, and Whole-Time Director, Mr. Surendran Chemmenkotil, Managing Director, and Mr. Sameer Patel, Chief Financial Officer of Metropolis Healthcare Limited. The call will start with opening remarks from management, after which we will move to a question-and-answer session. Thank you, and I'll hand things over to you, ma'am.
Thanks a lot, and good morning to all of you, and thank you for being with us today on the Q4 and FY 2026 earnings conference call for Metropolis Healthcare. As was noted, I'm here with Suren, Sameer, and Mohan, our CMO, along with the remaining leadership team and the IR advisors. Our investor presentation and the related documents have been posted on the stock exchanges and on the company's website. I trust all of you have had a chance to review them. Let me start with a quick view of the wider diagnostics landscape, and then I'll get into the company-specific updates. India's diagnostics industry keeps developing in a very positive direction. There is a consistent movement toward organized, trusted participants such as Metropolis, since doctors and consumers now place more weight on quality standards, scientific expertise, lab compliance, and a superior experience overall. This shift shows a market that is maturing, where trust and reliability are turning into the core of decision-making. Meanwhile, the industry is steadily progressing past growth led by routine testing, with a stronger contribution arriving from specialty diagnostics, wellness, and testing that is more complex and clinically relevant. Such areas don't just deepen diagnostic insights; they also match evolving healthcare needs more closely.
At the same time, deeper digital engagement, better consumer awareness, and growing attention to longitudinal health monitoring are opening up fresh opportunities for credible diagnostic platforms that operate at scale. That wider trajectory has also shown up in what we said in previous quarters, where preventive care, Specialty testing, AI-led enablement, genomics, and customer engagement have all been flagged by us on a consistent basis as the key structural forces driving future growth in this sector. Competition is a permanent feature, of course, yet we see a robust structural runway ahead for us, with no unreasonable or disruptive competitive dynamics. Metropolis stays well-positioned within the industry, since our moat rests on capabilities that are hard to replicate at scale. Consistent lab quality, deep and longstanding doctor engagement, strong scientific and clinical expertise, best-in-class tech platforms, and a highly standardized operating model across the network. Taken together, these elements form a foundation extending well past surface-level differentiation, and they support sustained performance over time. In diagnostics, trust gets built through the accuracy, consistency, and reliability of what happens behind the scenes in the lab, not merely through brand visibility and geographical reach. Institutional knowledge accumulated over years of experience further reinforces this backbone, making sure complex cases get handled with depth and accuracy.
That's still among the main reasons Metropolis keeps gaining the confidence of doctors and patients and holds its lead in premium diagnostics. When it comes to digital and AI, we stay pragmatic, deliberate, and centered on use cases that deliver the biggest impact. In pathology, we don't view AI as a disruptor over the near term; rather, it's a significant enabler of productivity, service quality, customer engagement, and workflow efficiency. During the last few quarters, we have bolstered our digital and AI tools across customer and partner platforms, lead management, workflow automation, and contact center quality along with selective diagnostic applications. Taken together, these efforts are assisting us in creating a more robust operating backbone, boosting productivity and efficiency, improving the customer experience, and fostering growth that is more scalable and sustainable in the years ahead. Our genomics journey has kept moving forward at a steady pace and stays a key strategic pillar for the future. Through the integration of Core Diagnostics and the continuous strengthening of our central genomics platform, we are expanding our capabilities in critical areas including oncology, reproductive health, inherited disorders, and precision diagnostics. That platform is now anchored by two CAP-accredited genomic labs in Gurgaon and Bombay, plus a growing team of genetic counselors throughout the country, which strengthens our capacity to provide high-end genomic testing with quality interpretation and at scale.
This integration has also let us widen access to high-end genomic testing throughout India via our B2C and B2B channels. Machines can be added by anyone, but what truly makes the difference in results is the personalized interpretation each patient requires, and that comes from institutional expertise and knowledge rather than from the equipment. As a result, Metropolis is increasingly seen as a trusted and credible leader in specialty genomics testing, with the capability to deliver advanced solutions at scale. Over time, we see genomics becoming a significant growth driver, especially in disease segments where precision, nuanced interpretation, and strong scientific engagement are essential. The participation and response we got at our recent genomics and scientific symposiums in Mumbai and Chennai have been so strong, clearly showing there are big gaps in the market for good clinical reports, which we can fill. We believe this strongly demonstrates the clinical trust in Metropolis and the relevance of the scientific platform we are continuing to build in genomics. At the same time, we continue to make steady progress on productivity and platform modernization. Across the last few quarters, we have worked on lab platform upgrades, infrastructure consolidation, vendor consolidation, and more optimal use of technology throughout the network.
What these initiatives are doing is making the operating backbone simpler, boosting efficiency, and helping us maintain structural cost discipline as time goes on. On the inorganic side too, integration is moving along largely as we expected. For Core Diagnostics, we had made a commitment that within 4 quarters of completing the acquisition, we would go from a -2% EBITDA to a high single-digit EBITDA in Q4. That mission is now complete. We remain on track for our three-year commitment of a 20%+ EBITDA at Core. During the last few quarters, our priority has been stabilization at Core — driving process alignment, integrating platforms, and capturing synergies across the acquired businesses so they are seamlessly embedded within the Metropolis umbrella and operating DNA. We are now starting to see tangible value emerge, not just from increased scale, but from enhanced capabilities, lab consolidation, better network utilization, procurement efficiencies, and a stronger foundation to support future growth. As we move forward, our focus will shift more toward driving volumes and scaling the platform. That, in turn, will unlock efficiencies and leverage, giving us a clear pathway for margin expansion over time. Turning to FY 2026, it has been a strong and well-executed year for Metropolis. We delivered organic revenue growth of 13.7%, which is better than the guidance of 12%-13% we had stated.
When you look at it on a normalized basis, organic margins rose roughly 140 basis points, reaching 25.9%, and that was underpinned by continuous gains in productivity, our ongoing work upgrading the lab platform, and consolidation efforts. As you're aware, we also completed a bonus share issue on March 26th aimed at improving the liquidity of our share for shareholders. I'm happy to report that the board has recommended a further interim dividend of INR 1 per share. That speaks to how solid our financial position is and to our ongoing dedication to building long-term value for shareholders. If we look back over the past three years, here is what we have achieved: organic revenue CAGR of 13% on a like-to-like basis, driven mostly by growth in test volume and patient volume. We brought organic revenue margins back to pre-COVID levels of approximately 26%. We grew lab capacity by over 50% and extended our footprint to more than 750 towns and cities throughout India. We cultivated a strong retail D2C mindset, and as a result self-referrals now make up 40% while the B2C business accounts for 60% of revenue, and both of these give us a stickier, higher-margin business model going forward. We moved into basic radiology and vital checks at certain centers on a pilot basis, and the response has been encouraging. Also, over the last three years, we built a robust technology architecture from the ground up, which let digital channels climb from 0%-25% of revenue and made the organization considerably more automated.
We likewise bolstered our scientific expertise and lifted how physicians and hospitals regard us, plus we brought in the whole genomics segment. That should produce improved price elasticity and the highest Specialty mix of anyone in the industry. We further grew our North India operations, taking what had been a mid-single digit share of revenue up to 17% of revenue. We brought in, upgraded, and built ahead of time a solid, higher-caliber management group capable of moving the business ahead. Looking out over the coming three years, here is the vision: to deliver a quicker 14%-15% revenue CAGR across three years. Organic revenue would mainly arrive through patient volumes, RPP growth, and price increases. A portion of it would additionally arrive by making strategic, value-additive acquisitions. Although we are setting a target for acquisitions, those would go ahead only when it is the right deal at the right price, and not merely for the sake of adding growth. We're going to reimagine our processes via automation and technology enablement to push center productivity and margin expansion, aiming to reach a sustainable group EBITDA margin of 27%-28% across the next three years, underpinned by profitability in every regional market and by lifting Core Diagnostics to a percent plus margin profile.
Our goal is to remain the most respected scientific brand — not only across the West and South of India but in the North and East as well — by cultivating trust and strong relationships with doctors. In addition, over the coming three years we are establishing a network of 100 mini hubs, covering pathology and basic radiology, to serve both retail and corporate clientele. Of those, 50 mini hubs will come from upgrading existing collection center locations, while the other 50 will be entirely new centers. Through these centers, we anticipate being able to deliver a broader range of services to our current B2C customers as well as to corporate clients and insurers. We intend to grow our asset-light collection center network by 1,500 additional centers. This shifts the lab-to-center ratio to 1:35 from the present 1:24, while lifting productivity at existing centers by 20% across three years. We also want to develop capability within Metropolis Healthcare to create a tech-enabled D2C vertical, concentrated on growing the chronic business acquired and serviced through digital and physical channels. Digital revenue at Metropolis Healthcare carries a higher customer lifetime value than the brick-and-mortar business, so increasing the digital contribution would boost RPP growth. On the whole, the business direction keeps getting stronger, with firmer foundations, sharper execution, and improved visibility going forward.
With that, I'll hand things over to Suren, who will walk you through how we performed operationally and what drove the business in the quarter and across the full year.
Thanks, Ameera. Morning, everyone. I'll walk you through how we performed this quarter and across the full year, then spend some time on the main business drivers — channels, network productivity, margins, and the operating outlook. In quarter four of 2026, MHL group revenue came in at INR 425 crore, up 23% year-on-year, with an EBITDA margin of 25.4%. Across the full year, revenue reached INR 1,646 crores, a rise of 23.6% year-on-year, with an EBITDA margin of 24.4%. Equally important, the quality underneath that growth is still solid, backed by patient growth, improved realization, a better mix, and productivity gains. Organically, revenue was up 14.7% in quarter four, mainly on patient volume growth of 9.3% and realization improvement of roughly 5%. For the full year, organic revenue growth came to 13.7%, as Ameera noted. It's also worth noting that, unlike last year, we didn't raise prices in Q4 because of GST reasons. That tells you the quarterly result came from healthy underlying demand, better mix, and stronger execution, which leaves the pricing lever as an opportunity for growth later in the year. Full-year 2026 mattered not only for the performance we delivered but also for the headway we made on a number of structural changes we began last year.
This includes reinforcing the network by consolidating labs and sharpening the center-to-lab ratio, pushing productivity and margin improvement efforts throughout the changes to the lab platform, cultivating a stronger and higher-quality B2B business, moving our M&A integration playbook forward, and advancing our digital agenda. Importantly, these aren't one-time actions. They're structural changes meant to enhance the quality and sustainability of growth in revenue and profitability over time. Let me begin with the channels. In B2C organic revenue, we keep seeing strong traction, with revenue growth of 14.7% in the quarter and 14% for the full-year. This was backed by healthy demand across wellness, Specialty, and routine testing, along with better customer engagement through both physical and digital channels. In B2B organic, revenue rose by 14.7% in quarter four and 13.3% for the year. We've been focused on improving ease of doing business, enhancing service consistency, deepening institutional and corporate relationships, and building a more sustainable portfolio with better unit economics. From a segment standpoint for organic revenue, TruHealth and Specialty continue to perform very strongly. TruHealth and Specialty grew by 20% and 17% respectively in the quarter, and by 21% and 16% respectively for the full-year.
These segments keep getting better on both customer engagement and the overall mix quality of the business. Now let me turn to network and productivity, since this is becoming a more and more important piece of our journey. During the past few years, we put substantial investment into growing and reinforcing our lab and service center backbone. That period of heavy build-out is now mostly behind us, and the emphasis has clearly moved away from expand-led CapEx toward throughput-led productivity. Put differently, what matters today isn't simply adding more infrastructure — it's generating more output, achieving better efficiency, and extracting stronger leverage from the infrastructure we've already created. That's a key shift in how we run the business and one of the significant drivers of margin improvement ahead. Over the year, we added 490 centers, which brought our total network to more than 5,000 collection centers spanning over 750 towns and 212 labs. Simultaneously, productivity across the existing network got better. With lab growth holding at about 14% and the center-to-lab ratio strengthening from 20:1 to 24:1. That stands as clear proof of the focused execution over the last year on boosting network density and driving higher throughput from the infrastructure we have already built.
Looking ahead across the coming 18 months, we anticipate further reinforcement of the feeder center network, pushing that ratio toward 30:1 in numerous markets, subject to how mature each cluster is. Across a three-year window, our aim is to reach a lab-to-center ratio of 35:1. Our productivity and margin agenda has been another key improvement driver this year. Throughout the year, we kept working on upgrading and standardizing lab testing platforms, consolidating equipment vendors, tightening inventory discipline via bar coding, and making more optimal use of technology in labs nationwide. These interventions are enhancing turnaround time, material productivity, and throughput throughout the network, and benefits began materializing in quarter four. We anticipate they will gain further strength over the next two quarters as implementation advances across the network. Organic EBITDA margin for the quarter was 27.2% versus 18.5% in the comparable period a year earlier, while full-year EBITDA margin reached 25.9%. Though the prior year margin was partly affected by one-time acquisition related costs at that time, EBITDA margin widened by 140 basis points even after adjusting for these costs. This gain stemmed from a combination of improved operating leverage, a stronger Specialty and wellness mix, productivity gains, integration synergies from acquisitions, and ongoing efficiency initiatives across industry.
Regarding acquisitions, the portfolio kept moving forward nicely. Core Diagnostics rose to a high single-digit margin in quarter four 2026, and Dehradun, Agra, Kolhapur continued running at margins above the company average. During the past several calls, we've made it clear that year one centers on integration, cleanup and efficiency, with revenue acceleration on a stronger platform to follow. Our view is that we're now creating a repeatable playbook for M&A integration spanning processes, people, systems, quality standards, and commercial synergies, and that will stay an important capability for us going forward. In summary, financial year 2026 was a year in which both our business fundamentals and our operating model became meaningfully stronger. As we exit the year, we are seeing strong momentum across multiple areas of the business. Patient volume growth remained healthy in the 7%-8% range, supported by the lab additions made over the last few years, continuous center expansion quarter after quarter, and the acceleration of our digital agenda. We are optimistic of sustaining the same going forward. At the same time, RPP growth is being driven by an improving mix led by enhanced TruHealth offerings, higher Specialty mix, and increasing contribution from genomics. Together, these drivers are helping us deliver consistent and broad-based revenue growth.
What matters here is that this expansion is matched by margin gains that can be sustained. Upgrades to our lab platform, efforts to consolidate vendors, and several productivity programs are now converting into greater operating leverage throughout the network. We are likewise making encouraging headway on lifting network productivity, improving the quality of the B2B business, and integrating the acquisition successfully via a playbook that is more structured and scalable. Especially encouraging is the fact that one-off factors are not what drives these gains; instead, they come from structural changes we have spent the last year putting in place across the business. That gives us confidence the business is growing not merely in size but in a way that is more sustainable, more efficient, and of higher quality. With that, I will pass things to Sameer, who will walk us through the details of the financial highlights. Thank you, and over to you, Sameer.
Thank you, Suren, and good morning to all of you. I'd like to take a brief moment to cover the group's key financial highlights and the full-year FY 2026 results for both the organic business and MHL group. We'll begin with the organic business. During both the quarter and the year, the organic business turned in a strong, consistent performance, powered by healthy growth in the B2B and B2C segments alike. Revenue for quarter four of FY 2026 came in at INR 392 crore, up 14.7% year-on-year, helped by 9% growth in patient volume and in test volume as well. Full-year FY 2026 revenue reached INR 1,510 crore, a rise of 13.7% year-on-year, with patient volume up 7.5% and test volume up 8%. For the quarter, B2C and B2B revenue each grew 15% year-on-year, while for the full year FY 2026, B2C revenue grew 14% and B2B revenue grew 13.3%. Our focus segment kept up its good performance. The TruHealth segment accounted for 19% of FY 2026 revenue and grew 21% year-on-year, while the Specialty segment accounted for 37% of revenue and grew 16% year-on-year. Turning to margins, quarter four's EBITDA was INR 107 crore at a margin of 27.2%, up 69% year-on-year. Full-year FY 2026 EBITDA came to INR 392 crore at a margin of 25.9%, which reflects 29% year-on-year growth.
For the fourth quarter, PAT was INR 55 crore, a 14.1% margin, up 89% year-on-year. For the full year FY 2026, PAT came in at INR 194 crore, with a 12.8% margin, a rise of 33% year-on-year. Now, on to how the MHL group performed. At the MHL group level, we stayed robust on revenue, volume, and profitability. Fourth-quarter FY 2026 revenue was INR 425 crore, up 23% year-on-year, with patient volume up 11% and test volume up 14%. Full-year FY 2026 revenue reached INR 1,646 crore, a 23.6% year-on-year increase, with patient and test volume growth of 12% and 13%, respectively. By channel, Q4 B2C revenue rose 20% year-on-year and B2B revenue rose 28% year-on-year. For the full year FY 2026, B2C revenue was up 19% year-on-year and B2B revenue up 31% year-on-year. Segment performance stayed splendid. The TruHealth segment accounted for 18% of FY 2026 revenue and grew 27% year-on-year. The Specialty segment made up 39% of revenue, with a strong 32% year-on-year growth. Profitability is still strong. Fourth-quarter EBITDA was INR 108 crore at a 25.4% margin, up 71% year-on-year. Full-year FY 2026 EBITDA came to INR 401 crore at a 24.4% margin, a 32% year-on-year increase.
For the fourth quarter, PAT came in at INR 51 crore, reflecting a 12% margin and a 75% increase compared with the same period a year earlier. On a full-year basis for FY 2026, PAT reached INR 191 crore at an 11.6% margin, up 31% year-over-year. Turning to capital expenditure for the year, we incurred CapEx, which amounted to INR 65 crore. As I mentioned before, our approach to allocating capital is growing more selective and more driven by productivity. Our investments today concentrate on adding network capacity in a targeted way, expanding Specialty tests, upgrading technology, and building digital capabilities. Since most of our lab network is now established, we expect future growth to gain from better operating leverage and higher productivity as volumes keep scaling. On that note, I'll hand things over for the Q&A session. Thank you.
Thanks a lot, sir. Ladies and gentlemen, we're now starting the question-and-answer portion. If you'd like to pose a question, you can hit star one on your touch-tone phone. Should you want to drop out of the queue, just enter star and two. We ask that participants use only handsets when asking a question. We'll pause briefly while the queue builds up. Our first question comes from Tausif at BNP Paribas. Please go ahead.
Morning, and thanks for taking the question. You've laid out guidance for revenue growth in the mid-teens across the coming 2 to 3 years. Could you add a bit more detail there? And over the last 2 quarters, has there been any structural movement from unorganized players toward organized ones, plus any competitive risk coming from online players?
Look, no third-party data exists that shows you the shift from unorganized to organized. Our read, from having people on the ground — the sense, as I said in the speech — is that a movement is underway in which consumers and doctors are gaining more comfort with larger brands, since those offer greater predictability. On top of that, the Specialty market is growing. Keep in mind that over the next 10 years, oncology and neurology are the two fastest-growing therapeutic segments worldwide. As more of these conditions come into India too, that means more Specialty tests will be performed rather than only routine ones — which naturally will occur with the more organized players and less with the unorganized ones. The mid-teens growth, 14%-15%, that we've guided for the next three years is clearly a mix of volume, RPP increase, and some price increase. That's how it breaks down.
Ma'am, are you planning to raise prices during this fiscal year?
So right now, a price increase isn’t something we’re considering, but if conditions change as the year goes on and we find that we need to make one, then no, we wouldn’t hold back from doing so.
All right, a quick follow-up about your guidance. You've guided to a better margin of 27%-28% over the next 2 to 3 years, but how would you view the next fiscal year? Would it fall in the range of 26%? That seems quite achievable.
We're certainly expecting something like 125 to 150 basis points of improvement in the year ahead.
All right, that helps. I’ll rejoin the queue.
Thanks. We’ll take the next question from Raman KV at Sequent Investments. Raman, your line is open and you can go ahead.
Yes, hi there. Are you able to hear me?
Yes, that's doable.
Right, just a quick follow-up there on the guidance side. You said growth will run at a 14%-15% CAGR across the coming three years. Of that, how much comes from volume growth — meaning patient volume growth — and how much comes from improved price realization out of Specialty and Core Diagnostics?
For the upcoming fiscal year, we're definitely estimating that patient volume growth will account for roughly 8%-9%. The other 5% is going to come from realization.
Got it, sir. Sir, my next question concerns the Specialty division. Over the last two years, the revenue contribution coming from Specialty has been roughly in the 35%-37% range, hovering there. Do you intend to raise your volume share within Specialty — that is, the contributions from your Specialty segment going forward? Do you consider this a healthy mix?
Sure, absolutely. I'd say there are two major levers available to us beyond the Specialty testing capabilities we already have in place. First, obviously, is the genomics path we've already begun and are speeding up. The second is the Core Diagnostics product capability that we possess, which we'll deploy across our network. In other words, those two items, on top of the Specialty portfolio we otherwise have, ought to be able to push the Specialty contribution even higher.
Do you expect it to be roughly 40% this year?
That's my view on it.
Okay.
Yeah.
All right, thank you, sir.
Thanks. Our next question comes from Sudarshan Agarwal at Axis Capital. The line is yours — go ahead.
Hi, thanks for taking my question. During the opening remarks, you mentioned that you're adding around 100 mini hubs. Could you explain what these are and how they differ from your collection centers, and how many exist in your current network? Also, what's the difference in CapEx needed for, say, a mini hub compared with your standard collection centers?
At a typical collection center, we obviously draw blood samples and then send them to the lab for testing. One thing we've done across the last 2 years is add some ECG, X-ray, and, at a limited number of sites, sonography too, basically to check whether doing so lets us raise RPP per patient. We've found that it has helped us. So now we want to go out and do this on a bigger scale. It won't be only about adding X-ray and ECG, but perhaps some additional basic radiology modalities. Not things like CT or MRI, but more basic modalities. For instance, that could include bone densitometry in some cases, a mammogram or mammography machine in some cases, or a larger X-ray machine in some cases. The basic idea is that you're building enough services locally. It isn't just blood, but blood plus radiology, plus in some cases it requires a consultation possibility. Making these into somewhat bigger, more serviced infrastructure centers, which can then be used not only for retail customers but for corporate customers as well.
Understood. For those centers, would capital expenditures come in at a higher level?
Absolutely.
By what amount?
The cost will exceed what a collection center runs, though it should land in roughly the same range as something like a lab — a satellite lab. At this point, our estimate is approximately INR 30 lakh to INR 40 lakh.
Okay, understood, thank you. Finally, just one more item on the accounting front. I was reviewing your bridge from organic to growth, you know. You said Core Diagnostics sits at high single digit, but when I take your MHL group revenues and EBITDA and subtract them down to your MHL organic figures, the M&A piece margin lands at roughly 4%–5%. Is there some inter-segment elimination going on there? Otherwise I just can't get those numbers to tie to high single digit.
Yeah.
Sure.
So let me explain what occurs when MHL brings in the business while the processing takes place on the Specialty side within the Core. When you get to the consolidation level, there's an elimination of that revenue along with the margin that would otherwise be present. That's why you're seeing what you see.
All right. So that benefit might actually be reflected in the organic margin you’re carrying.
Yeah. That's right.
Understood. Final item, just closing the books. Depreciation came up fairly steeply quarter over quarter. My assumption is that this reflects the genomic equipment you'd anticipated, or else something one-off or an impairment charge occurred in the quarter?
It's a combination of a few factors. The genomic machine has definitely arrived as well. The CapEx spending occurred later in the year, so the full depreciation impact shows up in quarter four. On top of that, network expansion was more aggressive during the second half. That's why those elements are showing up in depreciation.
Understood. Thanks — that's all from me.
Thanks. Our next question comes from Surya Patra at PhillipCapital, whose line is now open — go right ahead.
Yeah. Thanks for giving me the chance to ask, and congratulations on the great set of numbers. My first question is about the growth side. What I am seeing is that, okay, Tier 1, Tier 2, Tier 3, in the regions, the growth looks similar because the revenue mix is also similar on a YoY basis. The general understanding is that Tier 2 and Tier 3 should be growing faster than the cities, because the cities would be having all possible formats of competition.
What would you like to ask?
The question I have is this: shouldn't we be expecting stronger or quicker growth in the beyond Tier 1 market, and as a result, gradually improving growth as the mix shifts more toward that side?
Okay, so let me walk you through how the growth breaks down by tier — Tier 1 and Tier 2. On Tier 1, we've added the Core. As you know, Core Diagnostics is largely coming on in the Tier 1 setup, and you're seeing significantly stronger growth in Tier 1 over the last year. In a similar way, on Tier 2, you've got cities such as Dehradun, Agra and so on that got added, and you'll find stronger growth in Tier 2. In Tier 3, we're growing at roughly 26%-30% over the last few quarters. So without question, Tier 3 and above is delivering much higher growth, you know, compared with Tier 1 and Tier 2 on a like-to-like basis. That will keep being the case.
So, when we talk about these digital initiatives, should we think of them as a lever for expanding margins, or do they also drive volume?
It's really volume that comes first. Naturally, as you're aware, the expense of servicing is comparatively, well, lower than what a non-inorganic channel involves. Margins certainly improve as our digital revenue grows.
Alright.
To add one more point, it really hinges on how you bring a customer on board, correct? I mean, plenty of health tech companies out there are pursuing deep discounting as a way to acquire customers, and that isn't how Metropolis operates. If you go the deep discounting route for acquisition, then clearly that kind of business might lack solid unit economics and might not be profitable in a positive sense. The digital business that Metropolis is bringing in relies more on the strong brand we already have through physical channels on the ground, and that lets us consequently achieve a lower acquisition cost, a lower servicing cost, and a higher customer lifetime value, which could as a result deliver a better margin for Metropolis. That doesn't mean it's the benchmark for the entire industry.
Yes, ma'am. One more thing raised was inorganic growth, ma'am. Does any room exist there? Since it appears that way — okay, after completing Core Diagnostics, our attention now leans more toward the organic side. We also recognize that the targets in the diagnostics sector within India, if we look, are mostly standalone labs. So the chance for M&A seems restricted or smaller. What's your take on that, viewed through the lens of inorganic growth?
So, as you correctly pointed out, India does have those labs at around INR 3 lakh, and roughly 90% of them operate as single labs. Some regional chains have emerged, and there are plenty of assets out there that could be acquired. What we usually find is that a lot of these available assets may not meet the standards we set for what we want to purchase. We'll stay selective, but we keep seeing opportunities in play. We keep exploring them—obviously, when a candidate looks right and brings something strategic to us at the right price, that's when we move ahead and try to close a deal. Broadly speaking, I think we can expect inorganic activity to continue over the next few years.
Alright, just one thing I’d like to clarify on my end. What share of our, say, testing volume would be driven by insurers?
At this point, honestly, that's pretty negligible. Right now we don't have large volumes in the insurance segment. We're really just building a portfolio at this stage.
Absolutely, sir. Yes, thanks. All the best to you.
Much appreciated.
Thanks. Our following question comes from Shyam Srinivasan at Goldman Sachs. Go right ahead.
Good morning, and thanks for taking my question. I just have one about the opening remarks—the effort to raise productivity across our branches, or our network, by 20% for mature stores. Could you expand on that a bit, please?
We've established, let's say, 500 centers last year and 500 centers the year before that. In the early days, you know, once those centers are up and running, we simply focus on boosting walk-ins by working with doctors in the vicinity, and we're connecting with hospitals, clinics, and so on nearby. Also, you know, carrying out various other activities, you know, to engage customers in the neighborhood. That assists us in raising the productivity of every center we've opened. I mean, year on year, you know, roughly 8%-10% better productivity at the same center. Across a three-year span, we can certainly achieve a 20% gain from the same center that we set up over the last couple of years.
Yeah. Do we have a starting absolute figure? Like the correct numbers for each center — is there any metric along those lines?
For our own centers, for instance, the typical productivity is roughly INR 3.5 lakhs to INR 4 lakhs per center. When we open in year one, by the close of year one we're at about INR 1.5 lakhs, and we get that up to roughly INR 3 lakhs by the end of year three. Those are the figures for our own centers, and they're different for franchisee centers and rural centers.
Understood — that's quite useful. Thanks.
Yeah.
Let me follow up with a second question about the other remark on digital channels — the point that they're now contributing. Did I understand correctly when you said those channels account for 25% of revenue? If you could walk us through that, please. What kinds of measures are involved? I know we've been putting money into technology, but I just want to grasp what this channel actually is. Is it something like D2C, or am I missing something here?
No, those are mostly D2C. There are three separate channels I'd like to walk through. First, obviously, is our Metropolis app — that's where we bring customers in and interact with them. Second, we bring customers in via our website, where we prompt them to visit and submit a test request. The third is what we call our customer data platform, a CLM engine. With every current customer, we get in touch through digital channels and offer them the next best action — or, based on how they've tested in the past, what makes sense for them to do in the days ahead. Those are the three major initiatives we run to push digital customer acquisition.
That's useful, thanks. Wishing you the very best.
Thanks.
Thanks. Our following question comes from Alankar Garude at Kotak Institutional Equities. The line is yours — go ahead.
Morning, everyone. Sameer, could you go into more detail about the inter-segment eliminations, and how much longer will those eliminations keep going?
That’s going to be there permanently, because once we core the business, it’s going to handle the genomics business and the oncology businesses, and although revenue gets generated throughout the network, that’s the synergy benefit we’ll see. We’re expanding this test menu across the country to all of our clients and clinicians. That’s where the revenue will be generated, and then the processing will take place. That’s the reason intercompany transfers will occur and the elimination will be there.
Actually, let me just build on what Sameer mentioned. One of our goals is to generate high-end oncology revenue from the core products via the MHL distribution network. We'll continue ramping up that particular engine and begin moving an increasing share of core products through the MHL distribution engine. As revenue expands, there will naturally be more intercompany adjustments. At the group level, those get neutralized in any case, and we'll report the net figure at the group level, as you're aware.
Understood, sir. I'm just wondering whether, ideally, the inter-segment eliminations ought to be divided between organic and inorganic EBITDA when you present it in your presentation. Would that be a better way to do it, or do you feel that organic EBITDA is the true EBITDA as you report it in the presentation?
Look, we could honestly sit here and argue the fine points, but the fact is the acquisition has now been around for a year, and starting April 1st everything will be organic regardless. It genuinely makes no difference. All of it will be consolidated into the group in any case.
Alright.
Starting with the quarter one results, you're going to see just a single figure across all our, you know, presentation materials, and that's the organic or company-level number. We gave that last year because, you know, the acquisitions were only just taking place and integrations were still underway.
That's reasonable. For the second question, you've been posting a fairly solid rise in both revenue per patient and revenue per test, even though you haven't raised prices at all across the past few quarters. Premiumization and TruHealth have both been key contributors. On TruHealth specifically, given the visibility you have right now starting from 19%, how high could that mix go over the longer term?
Sure, this can certainly exceed 25% as well over the next two to three years. Each year, I think we're raising it by roughly a couple of percentage points. Perhaps in the years ahead we'll push our efforts further to, you know, speed it up. Because right now in the TruHealth packages, we're including vital checkup consults, basic radiology, you know, and also going forward, maybe we'll keep adding some of the other adjacent services. You know, the overall RPP will keep improving on the TruHealth packages. We'd like to see this moving faster, the TruHealth contribution moving faster in the years to come.
Got it, sir. That's all from me — thank you.
Thanks. We’ll take the next question from Kunal Thanvi at Banyan Tree Advisors. Your line is open — please go ahead.
Hi, thanks for taking the question. I had a couple of things. First, regarding the gross margin expansion we've seen, both for Metropolis and for Abhopay as well — if you could double-click on that and walk us through what's driving this improvement in gross margin. Is it purely the scale advantage coming through from our suppliers, or is it also related to some softening in on-ground competitive intensity over the last one year? That trend has held true for pretty much all the listed players, you know. That was my first question. My second one is on our core markets, something like Mumbai — what sort of volume growth are we seeing there? In a few concalls you mentioned that you've been gaining market share in core markets such as Mumbai as well. Is that trend still continuing? And the last one was, you've said the lab expansion is largely behind us, and from here on we'll see operating leverage. If you could again double-click on where utilization currently stands on a console basis and how that's expected to move around in FY 2027 and then going ahead.
There are 3 questions here. Thank you.
Alright, let me take the first question, which concerns the gross margin improvement. Two factors are genuinely assisting us in bettering the gross margin. First, as we said in our speech, we have carried out a lab platform consolidation and upgrades. We are simply consolidating a number of the vendors and shifting to better, more efficient, more productive, technology-enabled and scalable platforms. Through this process, we will obtain scale advantage. In this case, some advantages emerge from the technology, and overall our material consumption therefore improves. Also, during this year we introduced bar coding across all our 220 labs, which has additionally helped us enhance our material consumption percentages. The second factor we mentioned is that last year we did not significantly add any further new labs. Our lab addition phase ended, I mean, a year back. In the coming year as well, we are not planning to add a high number of labs in the network. These two factors will definitely be helping us to improve the gross margins.
Regarding your second question, what was it you said about that?
Volume.
On the Mumbai city volume front, I'd say it's pretty much tracking the company's overall volume growth. Give or take 1 percentage point here or there, those are the figures we're seeing across the geographies. Naturally, we're seeing considerably stronger patient volume growth in the northern part of the market for us — for this year, I mean — thanks to the new acquisitions we've completed there. Apart from that, by and large throughout the country we're achieving stable and solid patient volume growth across the board.
Yes, certainly. Regarding how much of the total lab capacity is being used?
We discussed the lab — you know, what would you call it — productivity increased by 14% over the course of this year, correct? That is the reason we aren't adding further labs and instead are adding more centers to feed them. Lab utilization, you know, rises. You see, all of these labs fall into a different category. You know, a few of them are large regional reference labs, a few are global labs, a few are satellite labs, and a few are greenfield labs. You know, giving a single figure for lab utilization per se in this business is very difficult for us. I mean, we can say more about it when we establish a lab, you know, we're only just beginning. Each year, if growth rises by 14%-15%, you know, that's utilization growth you can, you know, connect with.
Understood. If there's room for one more question, it concerns the following: when we discuss this productivity gain, the efficiency improvement, the deployment of technology, and so on—from a longer-term view, say 5 years or 10 years ahead, what sort of steady-state margins should this business carry? Given the gross margin expansion we've witnessed, at what point—when the expansion occurs, when most of the labs being added today reach, you know, an optimal level of utilization—is that 27%-28% EBITDA margin the target to achieve, or could margins over a longer period go even further if we don't, you know, opt to invest aggressively the way we've done in the last few years.
Margins can continue to grow as long as operating leverage exists, correct? In other words, if you keep expanding the business while costs rise more slowly, operating leverage remains available. Lastly, when building a business, you should view it across not just the short term but also the medium and long term, continually reinventing yourself and investing in strategic initiatives that let you create second and third growth engines for the future. In our view, maximizing the EBITDA may not be the smartest strategy. We think a sustainable EBITDA of 27%-28% over the next three years makes sense for us at this point. Should we be able to generate additional operating leverage, we would want to reinvest it in the business — whether through adding services, further building the brand, or building for the distribution. That is the direction we would like to take.
That makes sense. Wishing you all the best — thank you.
Thanks.
Thanks.
Thanks. Our next question comes from Kaustav Bubna at BMSPL, so please go ahead.
Hi, thanks for taking my question. Earlier, you said growth in Tier 1 areas is under single digits. I'd like to really understand this, because take Mumbai, for instance, right? Even a Tier 1 city like Mumbai breaks down into different areas where consumption patterns would differ, given the kinds of people with varying income levels living in those areas. Take Bombay, for example, right, and ask what your growth rate—expected growth rate—would be in a place like Mumbai. If you actually had to break that down across Mumbai's areas—like, you know, north, south, a more eastern area like the Kalyan side, etc.—what would you say Metropolis', how do you call it, presence is in these areas, and how would growth rates differ across these different areas in Mumbai?
Mumbai, as you're aware, is our largest market. We have roughly 500 service centers throughout Mumbai—not just within the metropolitan area but also stretching out across, you know, even the city's outskirts. We're there wherever you look, whether that's Kalyan or Borivali or, I mean, Virar, Vasai. I mean, we're spread across all these areas, and we keep expanding the network print footprint here. That's an ongoing process. In Mumbai, we're also growing at a revenue growth of 13%-14% on a year-on-year basis. It would be hard for me to share further micro market segmentation of Mumbai and tell you how much growth Kalyan has, how much growth Thane has. That would be very difficult for me to share with you. At an overall level, most parts of Mumbai are growing at a growth of 13%, 14%.
I want to be clear on this—I believe Tier 1 growth isn't in the single digits; it's nearer to 11%.
Alright, thanks.
Thank you. Because we're running short on time, ladies and gentlemen, that question will have to be the final one. At this point, I'll pass things over to management for their closing remarks.
Thanks, everyone, for being with us today for the Q4 and FY 2026 earnings call. We really appreciate the engagement and all the questions. It's been quite a tremendous year — not just a year of strong organic growth, but also one of fundamental building, which has helped us expand margins quite significantly as well. It was also a year in which we completed four acquisitions and not only absorbed them but seamlessly integrated them into the business. You know, obviously realizing a very fast growth rate of about 23.6% for the whole year. We're very, very excited and positive about the next three years; we believe we have three or four channels, or three or two sort of pillars. We'll keep building the business very strongly. We're doubling down on technology. We're doubling down on building engagement with our consumers and building the brand through experience, and doubling down on science, and really building the scientific foundation even stronger. Obviously all of this is going to be enabled by the right people, the right talent, and finally to result in a commercially stronger business and a bigger business, in the next few years to come.
Our enthusiasm hasn't faded at all, and we can't wait to see all of you before long. We're also eager to start putting together what you might call a day at our lab, at some point in June or July. We'll be reaching out to many of you again, since it would be our pleasure to welcome you, give you a tour, and go even deeper in conversation. Many thanks to all of you.
Thanks a lot. That brings this conference call to a close on behalf of Ambit Capital. Appreciate everyone for being with us, and you can go ahead and disconnect your lines now. Thank you.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Metropolis Healthcare Limited transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Metropolis Healthcare Limited earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.